FR15C0089I2 - Antagonistes de recombinaison de l'il-5 utiles dans le traitement des troubles induits par l'il-5 - Google Patents
Antagonistes de recombinaison de l'il-5 utiles dans le traitement des troubles induits par l'il-5Info
- Publication number
- FR15C0089I2 FR15C0089I2 FR15C0089C FR15C0089C FR15C0089I2 FR 15C0089 I2 FR15C0089 I2 FR 15C0089I2 FR 15C0089 C FR15C0089 C FR 15C0089C FR 15C0089 C FR15C0089 C FR 15C0089C FR 15C0089 I2 FR15C0089 I2 FR 15C0089I2
- Authority
- FR
- France
- Prior art keywords
- recombination
- treatment
- antagonists useful
- induced disorders
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Otolaryngology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36313194A | 1994-12-23 | 1994-12-23 | |
US08/470,110 US5693323A (en) | 1994-12-23 | 1995-06-06 | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
US08/467,420 US5683892A (en) | 1994-12-23 | 1995-06-06 | DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
PCT/US1995/017082 WO1996021000A2 (en) | 1994-12-23 | 1995-12-22 | Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
FR15C0089I2 true FR15C0089I2 (fr) | 2016-07-01 |
FR15C0089I1 FR15C0089I1 (el) | 2016-12-02 |
Family
ID=23428947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR15C0089C Active FR15C0089I2 (fr) | 1994-12-23 | 2015-12-16 | Antagonistes de recombinaison de l'il-5 utiles dans le traitement des troubles induits par l'il-5 |
Country Status (11)
Country | Link |
---|---|
US (5) | US5683892A (el) |
EP (1) | EP1749840A3 (el) |
JP (2) | JP5177444B2 (el) |
KR (1) | KR100511544B1 (el) |
CN (1) | CN101353381A (el) |
CY (2) | CY2592B2 (el) |
FR (1) | FR15C0089I2 (el) |
HU (1) | HUS1500070I1 (el) |
NO (1) | NO2018035I1 (el) |
PT (1) | PT800536E (el) |
ZA (1) | ZA9510965B (el) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7399837B2 (en) | 1995-12-22 | 2008-07-15 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
HU222992B1 (hu) * | 1994-12-23 | 2004-01-28 | Smithkline Beecham Corporation | IL-5 Mediált rendellenességek kezelésére használható rekombináns IL-5 antagonisták |
US5683892A (en) * | 1994-12-23 | 1997-11-04 | Smithkline Beecham Corporation | DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
FR2783326B1 (fr) * | 1998-09-10 | 2000-12-01 | Immunotech Sa | Procede de detection ou de quantification des basophiles et des eosinophiles |
WO2001025277A1 (en) * | 1999-10-07 | 2001-04-12 | Maxygen Aps | Single-chain antagonist polypeptides |
WO2003085089A2 (en) * | 2002-03-29 | 2003-10-16 | Schering Corporation | Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same |
US7718076B1 (en) | 2006-02-14 | 2010-05-18 | Charles Lonnie Meurer | Methods of and common gantry drive for single-pass cleaning of multiple stages of a material separation and removal system |
US7780015B1 (en) | 2006-08-24 | 2010-08-24 | Meurer Research, Inc. | Methods of and sludge collector with adjacent opposed oppositely-moving blades for moving sludge in a basin |
JP2010526088A (ja) | 2007-04-30 | 2010-07-29 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 抗il−5抗体を投与するための方法 |
EA201071137A1 (ru) | 2008-03-28 | 2011-04-29 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Способы лечения |
BR112013016235B1 (pt) | 2010-12-22 | 2020-03-31 | Cephalon Australia Pty Ltd | Anticorpo isolado, uso de um anticorpo, ácido nucleico, célula transformada e composição farmacêutica |
WO2013157102A1 (ja) * | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ5ac特異的ヒト化抗体およびその利用 |
WO2013157105A1 (ja) * | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ5ac特異的ヒト化抗体およびその利用 |
EA037487B1 (ru) | 2015-08-24 | 2021-04-02 | Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед | Биофармацевтические композиции |
AR110564A1 (es) * | 2016-12-23 | 2019-04-10 | Cephalon Inc | Anticuerpos anti-il-5 |
WO2018143938A1 (en) * | 2017-01-31 | 2018-08-09 | Msm Protein Technologies Inc. | Anti-cxcr4 antibodies |
AU2018219864A1 (en) | 2017-02-10 | 2019-08-29 | Mayo Foundation For Medical Education And Research | Trailshort antibody and methods of use |
KR102473898B1 (ko) * | 2017-05-26 | 2022-12-07 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 생물제약 조성물 및 관련 방법 |
CN110913887A (zh) | 2017-06-06 | 2020-03-24 | 葛兰素史克有限责任公司 | 用于儿科患者的生物药物组合物和方法 |
KR102709785B1 (ko) * | 2017-09-29 | 2024-09-24 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Il-5 항체, 이의 항원 결합 단편 및 이의 의학적 적용 |
CN109942706A (zh) * | 2017-12-21 | 2019-06-28 | 三生国健药业(上海)股份有限公司 | 结合人il-5的单克隆抗体、其制备方法和用途 |
CN111303284A (zh) * | 2018-12-12 | 2020-06-19 | 尚华科创投资管理(江苏)有限公司 | 抗人白细胞介素5(il-5)单克隆抗体及其应用 |
CN113769081A (zh) * | 2020-06-10 | 2021-12-10 | 三生国健药业(上海)股份有限公司 | 一种稳定的高浓度抗人il-5单克隆抗体液体制剂 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8800397D0 (en) * | 1988-01-08 | 1988-02-10 | Sandoz Ltd | Improvements in/relating to organic compounds |
IL92180A (en) * | 1988-11-03 | 1997-04-15 | Schering Corp | Pharmaceutical composition for preventing or reducing eosinophilia |
US5096704A (en) * | 1988-11-03 | 1992-03-17 | Schering Corporation | Method of treating eosinophilia |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
RU2128709C1 (ru) * | 1992-01-23 | 1999-04-10 | Мерк Патент Гмбх | Способ получения димерного одноцепочечного слитого белка (варианты) |
NZ249633A (en) * | 1992-02-06 | 1995-12-21 | Schering Corp | Monoclonal and humanised antibodies to interleukin-5, their production, use and methods for producing humanised antibodies. |
JPH06141885A (ja) * | 1992-11-05 | 1994-05-24 | Chemo Sero Therapeut Res Inst | モノクローナル抗体 |
WO1995014040A1 (en) | 1993-11-19 | 1995-05-26 | Baylor College Of Medicine | Monoclonal antibodies specific for human interleukin-5 |
GB9412230D0 (en) * | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
US5683892A (en) * | 1994-12-23 | 1997-11-04 | Smithkline Beecham Corporation | DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
HU222992B1 (hu) * | 1994-12-23 | 2004-01-28 | Smithkline Beecham Corporation | IL-5 Mediált rendellenességek kezelésére használható rekombináns IL-5 antagonisták |
US5783184A (en) * | 1994-12-23 | 1998-07-21 | Smithkline Beecham Corporation | Method for treatment and diagnosis of IL-5 mediated disorders |
WO2001012646A1 (en) | 1999-08-19 | 2001-02-22 | Smithkline Beecham Corporation | Sialoadhesin factor-1 agonist and antagonist antibodies |
-
1995
- 1995-06-06 US US08/467,420 patent/US5683892A/en not_active Expired - Lifetime
- 1995-06-06 US US08/470,110 patent/US5693323A/en not_active Expired - Lifetime
- 1995-12-22 EP EP06124848A patent/EP1749840A3/en not_active Ceased
- 1995-12-22 CN CNA200710186675XA patent/CN101353381A/zh active Pending
- 1995-12-22 KR KR10-2004-7015736A patent/KR100511544B1/ko not_active IP Right Cessation
- 1995-12-22 PT PT95944692T patent/PT800536E/pt unknown
- 1995-12-27 ZA ZA9510965A patent/ZA9510965B/xx unknown
-
1997
- 1997-09-30 US US08/940,371 patent/US5851525A/en not_active Expired - Lifetime
-
2002
- 2002-05-13 US US10/144,644 patent/US20030059429A1/en not_active Abandoned
-
2003
- 2003-11-04 US US10/700,740 patent/US6946130B2/en not_active Expired - Fee Related
-
2008
- 2008-05-16 CY CY0800009A patent/CY2592B2/xx unknown
-
2009
- 2009-10-23 JP JP2009244448A patent/JP5177444B2/ja not_active Expired - Lifetime
-
2012
- 2012-10-02 JP JP2012220614A patent/JP2013091636A/ja active Pending
-
2015
- 2015-12-16 FR FR15C0089C patent/FR15C0089I2/fr active Active
- 2015-12-17 HU HUS1500070C patent/HUS1500070I1/hu unknown
- 2015-12-18 CY CY2015056C patent/CY2015056I1/el unknown
-
2018
- 2018-10-04 NO NO2018035C patent/NO2018035I1/no unknown
Also Published As
Publication number | Publication date |
---|---|
JP2010077133A (ja) | 2010-04-08 |
EP1749840A3 (en) | 2008-10-15 |
NO2018035I1 (no) | 2018-10-04 |
CY2015056I1 (el) | 2016-08-31 |
HUS1500070I1 (hu) | 2017-07-28 |
ZA9510965B (en) | 1996-09-16 |
JP5177444B2 (ja) | 2013-04-03 |
CN101353381A (zh) | 2009-01-28 |
KR100511544B1 (ko) | 2005-08-31 |
CY2592B2 (en) | 2009-11-04 |
US5693323A (en) | 1997-12-02 |
US5851525A (en) | 1998-12-22 |
US20040156850A1 (en) | 2004-08-12 |
US5683892A (en) | 1997-11-04 |
KR20040101388A (ko) | 2004-12-02 |
CY2015056I2 (el) | 2016-06-22 |
PT800536E (pt) | 2007-02-28 |
EP1749840A2 (en) | 2007-02-07 |
JP2013091636A (ja) | 2013-05-16 |
US20030059429A1 (en) | 2003-03-27 |
US6946130B2 (en) | 2005-09-20 |
FR15C0089I1 (el) | 2016-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR15C0089I2 (fr) | Antagonistes de recombinaison de l'il-5 utiles dans le traitement des troubles induits par l'il-5 | |
BR9407575A (pt) | Recombinaçao il4 de anticorpos uteis no tratamento de desordens do il4 | |
FR2647675B1 (fr) | Utilisation d'un derive de la statine dans le traitement des affections oculaires | |
BR9305310A (pt) | Conjunto de came e conjunto de came "S" | |
FR2741355B1 (fr) | Composition pour le traitement d'objets que l'on souhaite nettoyer et/ou desinfecter | |
MA24169A1 (fr) | Traitement de l'asthme a l'aide de la tnfr-ig | |
GB9111089D0 (en) | Improvements in or relating to the treatment of waste | |
HUP0000570A3 (en) | Use of 17 alpha-dihydroequilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states | |
ES1022183Y (es) | "arropamiento de cama perfeccionado" | |
KR950031762U (ko) | 브라케트의 효율적인 구조 | |
FR2744637B1 (fr) | L'exerciseur des cuisses et des fessiers | |
IT1283294B1 (it) | Unita' di filatura | |
ITMC940040A0 (it) | Dispositivo per tenere sveglio l'autista | |
KR940006018U (ko) | 보일러의 배풍기 고정구조 | |
KR960012047U (ko) | 마이컴의 키메트릭스 확장장치 | |
ITMI940214A0 (it) | Dispositivo perfezionato per attuare l'auto-insufflazione nel trattamento dell'otite media | |
SE9403120L (sv) | Overall "Easy" | |
KR950024858U (ko) | 카리프트의 풋보드 확장장치 | |
KR950011928U (ko) | 사류팬의 허브 | |
ES1022040Y (es) | "tapon-precinto perfeccionado" | |
KR950024510U (ko) | 운전자용 졸음 방지구 | |
ITMI941045A0 (it) | Difosfonati e loro impiego farmacologico nel trattamento dell'osteoporosi | |
IT1273853B (it) | Distributore gravitazionale per microcomponenti automaticamente allineati ed orientati all'unita' | |
KR960031066U (ko) | 자동차용 인사이드 밀러의 체결구조 | |
LV5177A3 (lv) | Preparats "eridons" govju endometritu profilaksei un arstesanai |